Pfizer (PFE)
(Delayed Data from NYSE)
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Pfizer's (PFE) Q3 Loss Narrows, Sales Miss on COVID Slump
by Zacks Equity Research
Pfizer (PFE) reports mixed third-quarter 2023 results. It re-affirms its 2023 sales and earnings guidance provided earlier this month.
Markets Wait for Fed's FOMC Meeting Decisions
by Zacks Equity Research
Markets Wait for Fed's FOMC Meeting Decisions.
UAW Wins; CAT & PFE Beat, Fall in Pre-Market
by Mark Vickery
This morning, a muted version of yesterday's bull market continues: the Dow is +2 points, and the S&P 500 and the Nasdaq are +6.
Compared to Estimates, Pfizer (PFE) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Pfizer (PFE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 46.88% and 3.93%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Deciphera (DCPH) Stock Gains 17% on Q3 Earnings & Sales Beat
by Zacks Equity Research
Deciphera (DCPH) reports better-than-expected third-quarter 2023 results, wherein earnings and revenues beat estimates, driven by increased Qinlock sales. The stock rises 17%.
Drug, Biotech Stocks' Q3 Earnings Due on Oct 31: AMGN, PFE, INCY
by Zacks Equity Research
Let's take a look at three biotech/drug companies, AMGN, PFE and INCY, slated to release quarterly results on Oct 31.
Pre-Markets in Green to Start a Crucial Week of Events
by Zacks Equity Research
Pre-Markets in Green to Start a Crucial Week of Events.
Busy Week for Earnings, Fed, Reports; MCD, ON Beat in Q3
by Mark Vickery
Mid-October near-term highs have given way to lower trading levels for the most part in the past couple weeks.
The Zacks Analyst Blog Highlights Costco Wholesale, Pfizer, IBM, NextEra Energy and HCA Healthcare
by Zacks Equity Research
Costco Wholesale, Pfizer, IBM, NextEra Energy and HCA Healthcare are part of the Zacks top Analyst Blog.
Pfizer's (PFE) Key Drugs to Drive Q3 Earnings Amid COVID Decline?
by Zacks Equity Research
Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.
Top Research Reports for Costco, Pfizer & IBM
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corp. (COST), Pfizer Inc. (PFE) and IBM Corp. (IBM).
Pharma Stock Roundup: SNY, MRK, NVS Report Q3 Earnings, FDA Okays PFE, LLY Products
by Kinjel Shah
Merck (MRK), Sanofi (SNY) and Novartis (NVS) report third-quarter results. FDA approves Pfizer's (PFE) Penbraya and Eli Lilly's (LLY) Omvoh
AbbVie (ABBV) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of 3.15% and 1.65%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Eli Lilly (LLY) Q3 Earnings Expected to Decline
by Zacks Equity Research
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Pfizer (PFE) Q3 Earnings Expected to Decline
by Zacks Equity Research
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pfizer (PFE) to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $30.84, moving +0.62% from the previous trading session.
Charles River (CRL) Offers Access to Preclinical Cancer Research
by Zacks Equity Research
Charles River (CRL) contributes to 84 percent of the FDA-approved cancer medicines and provides partners with 16 oncology prospects.
Pharma Stock Roundup: JNJ Posts Upbeat Q3 Earnings, PFE, NVO Revise 2023 View
by Kinjel Shah
J&J (JNJ) reports strong third-quarter results. Merck's (MRK) new deal with Japan's Daiichi Sankyo to jointly develop the latter's three DXd ADC candidates.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer (PFE) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Pfizer (PFE) concluded the recent trading session at $32.75, signifying a -1.56% move from its prior day's close.
Moderna (MRNA) Down Despite Maintaining COVID Jab Sales View
by Zacks Equity Research
Though Moderna (MRNA) reiterated its sales guidance for COVID vaccine, it warned investors that it could not predict exact demand yet.
Nu Holdings and Tyson Foods have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Nu Holdings and Tyson Foods have been highlighted as Zacks Bull and Bear of the Day.
Johnson & Johnson (JNJ) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 5.56% and 1.67%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?